Summary

Hyponatremia is the most common clinically encountered serum electrolyte abnormality, occurring in 7% to 8% of elderly, ambulatory patients and 15% to 20% of hospitalized patients [Huda MS et al. Postgrad Med J 2006]. This article reports on a prospective clinical trial that evaluated the effect of the selective, competitive vasopressin 2 antagonist tolvaptan in the treatment of hyponatremia [Koren MJ et al. ICE ENDO 2014 (poster LBSA-0737)].